ANX1439

ANX1439 is a small molecule inhibitor of the classical complement pathway, specifically targeting the **Complement C1s protease**. It is the active metabolite of the prodrug **ANX1502**, which is being developed by **Annexon Biosciences**. By selectively inhibiting C1s, ANX1439 prevents the activation of the classical complement cascade, a process implicated in various autoimmune and neurodegenerative disorders. The drug is designed for oral administration via its prodrug form to provide a more convenient therapeutic option compared to existing injectable complement inhibitors. Clinical development has initially focused on safety and pharmacokinetics in healthy volunteers, with broader potential applications in autoimmune diseases such as Cold Agglutinin Disease (CAD) and Myasthenia Gravis (MG).